Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
09 2020
Historique:
received: 13 05 2020
revised: 25 06 2020
accepted: 30 06 2020
pubmed: 5 8 2020
medline: 9 2 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

SENTIX (ENGOT-CX2/CEEGOG-CX1) is an international, multicentre, prospective observational trial evaluating sentinel lymph node (SLN) biopsy without pelvic lymph node dissection in patients with early-stage cervical cancer. We report the final preplanned analysis of the secondary end-points: SLN mapping and outcomes of intraoperative SLN pathology. Forty-seven sites (18 countries) with experience of SLN biopsy participated in SENTIX. We preregistered patients with stage IA1/lymphovascular space invasion-positive to IB2 (4 cm or smaller or 2 cm or smaller for fertility-sparing treatment) cervical cancer without suspicious lymph nodes on imaging before surgery. SLN frozen section assessment and pathological ultrastaging were mandatory. Patients were registered postoperatively if SLN were bilaterally detected in the pelvis, and frozen sections were negative. ClinicalTrials.gov (NCT02494063). We analysed data for 395 preregistered patients. Bilateral detection was achieved in 91% (355/395), and it was unaffected by tumour size, tumour stage or body mass index, but it was lower in older patients, in patients who underwent open surgery, and in sites with fewer cases. No SLN were found outside the seven anatomical pelvic regions. Most SLN and positive SLN were localised below the common iliac artery bifurcation. Single positive SLN above the iliac bifurcation were found in 2% of cases. Frozen sections failed to detect 54% of positive lymph nodes (pN1), including 28% of cases with macrometastases and 90% with micrometastases. SLN biopsy can achieve high bilateral SLN detection in patients with tumours of 4 cm or smaller. At experienced centres, all SLN were found in the pelvis, and most were located below the iliac vessel bifurcation. SLN frozen section assessment is an unreliable tool for intraoperative triage because it only detects about half of N1 cases.

Sections du résumé

BACKGROUND
SENTIX (ENGOT-CX2/CEEGOG-CX1) is an international, multicentre, prospective observational trial evaluating sentinel lymph node (SLN) biopsy without pelvic lymph node dissection in patients with early-stage cervical cancer. We report the final preplanned analysis of the secondary end-points: SLN mapping and outcomes of intraoperative SLN pathology.
METHODS
Forty-seven sites (18 countries) with experience of SLN biopsy participated in SENTIX. We preregistered patients with stage IA1/lymphovascular space invasion-positive to IB2 (4 cm or smaller or 2 cm or smaller for fertility-sparing treatment) cervical cancer without suspicious lymph nodes on imaging before surgery. SLN frozen section assessment and pathological ultrastaging were mandatory. Patients were registered postoperatively if SLN were bilaterally detected in the pelvis, and frozen sections were negative.
TRIAL REGISTRATION
ClinicalTrials.gov (NCT02494063).
RESULTS
We analysed data for 395 preregistered patients. Bilateral detection was achieved in 91% (355/395), and it was unaffected by tumour size, tumour stage or body mass index, but it was lower in older patients, in patients who underwent open surgery, and in sites with fewer cases. No SLN were found outside the seven anatomical pelvic regions. Most SLN and positive SLN were localised below the common iliac artery bifurcation. Single positive SLN above the iliac bifurcation were found in 2% of cases. Frozen sections failed to detect 54% of positive lymph nodes (pN1), including 28% of cases with macrometastases and 90% with micrometastases.
INTERPRETATION
SLN biopsy can achieve high bilateral SLN detection in patients with tumours of 4 cm or smaller. At experienced centres, all SLN were found in the pelvis, and most were located below the iliac vessel bifurcation. SLN frozen section assessment is an unreliable tool for intraoperative triage because it only detects about half of N1 cases.

Identifiants

pubmed: 32750501
pii: S0959-8049(20)30367-1
doi: 10.1016/j.ejca.2020.06.034
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02494063']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-80

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare no conflict of interest.

Auteurs

David Cibula (D)

Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Electronic address: david.cibula@vfn.cz.

Roman Kocian (R)

Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Andrea Plaikner (A)

Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, Hamburg, Germany.

Jiri Jarkovsky (J)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Jaroslav Klat (J)

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.

Ignacio Zapardiel (I)

Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.

Radovan Pilka (R)

Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic.

Aureli Torne (A)

Unit of Gynecological Oncology, Institute Clinic of Gynaecology, Obstetrics, and Neonatology, Hospital Clinic-Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Borek Sehnal (B)

Department of Obstetrics and Gynecology, Bulovka Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Marcela Ostojich (M)

Department of Gynecology, Institute of Oncology Angel H. Roffo, University of Buenos Aires, Buenos Aires Autonomous City, Argentina.

Almerinda Petiz (A)

Department of Gynecology, Francisco Gentil Portuguese Oncology Institute, Porto, Portugal.

Octavio A Sanchez (OA)

Department of Gynecologic Oncology, University Hospital of the Canary Islands, Las Palmas de Gran Canaria, Spain.

Jiri Presl (J)

Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.

Alessandro Buda (A)

Department of Obstetrics and Gynecology, Unit of Gynecologic Oncology Surgery, San Gerardo Hospital, Monza, Italy.

Francesco Raspagliesi (F)

Fondazione IRCCS Istituto Nazionale Tumori - Milan, Milan, Italy.

Peter Kascak (P)

Department of Obstetrics and Gynecology, Faculty Hospital Trencin, Trencin, Slovakia.

Luc van Lonkhuijzen (L)

Center for Gynecologic Oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Marc Barahona (M)

Department of Gynecology, University Hospital of Bellvitge, Biomedical Research Institute of Bellvitge, University of Barcelona, Barcelona, Spain.

Lubos Minar (L)

Department of Gynecology and Obstetrics, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Pawel Blecharz (P)

Department of Gynecologic Oncology, Centre of Oncology, M. Sklodowska-Curie Memorial Institute, Cracow Department, Cracow, Poland.

Maja Pakiz (M)

University Clinic for Gynaecology and Perinatology, University Medical Centre Maribor, Maribor, Slovenia.

Dariusz Wydra (D)

Department of Gynecology, Gynecologic Oncology and Gynecologic Endocrinology, Medical University of Gdansk, Poland.

Leon C Snyman (LC)

Gynaecologic Oncology Unit, Department of Obstetrics and Gynaecology, University of Pretoria, Pretoria, South Africa.

Kamil Zalewski (K)

Department of Gynecologic Oncology, Holycross Cancer Center, Kielce, Poland.

Cristina Zorrero (C)

Gynecology Department, Instituto Valenciano de Oncologia (IVO), Valencia, Spain.

Pavel Havelka (P)

Department of Obstetrics and Gynecology, KNTB a.s Zlin, Czech Republic.

Mikulas Redecha (M)

Department of Gynaecology and Obstetrics, University Hospital, Comenius University, Bratislava, Slovakia.

Alla Vinnytska (A)

LISOD - Israeli Oncological Hospital, Plyuty, Ukraine.

Ignace Vergote (I)

Department of Gynecology and Obstetrics, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium.

Solveig Tingulstad (S)

Department of Gynaecology, St Olav's Hospital, Trondheim, Norway.

Martin Michal (M)

Department of Obstetrics and Gynaecology, Hospital Ceske Budejovice, JSC, Ceske Budejovice, Czech Republic.

Barbara Kipp (B)

Department of Obstetrics and Gynecology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.

Jiri Slama (J)

Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Simone Marnitz (S)

Department of Radiation Oncology, CyberKnife and Radiotherapy University Hospital Cologne, Cologne, Germany.

Sylva Bajsova (S)

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.

Alicia Hernandez (A)

Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.

Daniela Fischerova (D)

Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Kristyna Nemejcova (K)

Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Christhardt Kohler (C)

Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH